Dose Insider / Outsourcing pharmacies / BayCare Integrated Service Center, LLC dba BayCare Central Pharmacy

BayCare Integrated Service Center, LLC dba BayCare Central PharmacyFDA registration and inspection record

FDA list of November 17, 2026 · checked against fda.gov on November 20, 2026

BayCare Integrated Service Center, LLC dba BayCare Central Pharmacy in Temple Terrace, Florida is registered with FDA as a 503B outsourcing facility, first on June 4, 2019 and most recently on February 5, 2026.

9 observationsin the Form 483 of FDA’s inspection on March 12, 2026
Observations in the last Form 483FDA inspection reports of registered outsourcing facilitiesThis facility9Median facility5Most in one report16Observations in the lastForm 483FDA inspection reports of registered outsourcingfacilitiesThis facility9Median facility5Most in one report16

BayCare Integrated Service Center, LLC dba BayCare Central Pharmacy had more observations than the median inspected facility.

On this page

FDA last inspected it on March 12, 2026 and issued a Form 483 with 9 observations.

These facts come from FDA’s list of registered outsourcing facilities, updated November 17, 2026, and from the inspection report FDA posted with it.1 None of the 164 FDA warning letters about GLP-1 drugs in our database names this company.

What does FDA’s record show, in brief?

FacilityBayCare Integrated Service Center, LLC dba BayCare Central Pharmacy
LocationTemple Terrace, Florida
Type503B outsourcing facility
Registered sinceJune 4, 2019
Latest registrationFebruary 5, 2026
Last FDA inspectionMarch 12, 2026
Inspection dates2/17/2026 to 3/12/2026
Form 483Issued, 9 observations
FDA action after the inspectionFMD-145 Letter Issued 9/18/202
Compounds sterile drugs from bulkNo
FDA warning letters on GLP-1 drugs0

What did FDA’s investigators observe?

The Form 483 from the inspection of 3/12/2026 lists 9 observations. We sorted them by what each one is about, from the words of its opening sentence; the full wording is in FDA’s document.2

What the observation is aboutObservations
Sterility and aseptic processing4
Labeling and records2
Environmental and personnel monitoring2
Cleaning and disinfection1

FDA’s scan of the form is an image with a text layer; we do not quote it here because the text layer misreads some letters. Read the original on fda.gov.

Has this facility recalled any drugs?

FDA’s enforcement reports list 3 recalled products from this facility, from July 30, 2021 to December 1, 2022: 1 in Class I, 1 in Class II, 1 in Class III. None of them names a GLP-1 drug. Class I is the most serious: FDA uses it when the product could cause serious harm.3

StartedClassProductReason
2022-12-01IIohexol (300 mg Iodine/mL)Labeling: Label Error on Declared Strength: syringes mislabeled as 300 mg iodine/mL contained product 350 mg iodine/mL
2022-02-14IIINorepinephrine bitartrate 16 mg in 250 mL NaCl 0.9%Subpotent drug
2021-07-30IISuccinylcholine Chloride 100 mg/5 mL (20 mg/mL)Lack of sterility assurance

Is the pharmacy behind my prescription on FDA’s list?

Type a pharmacy name or city. The search runs over all 100 facilities on FDA’s list; a 503A pharmacy that compounds for individual prescriptions is licensed by its state and is not on this list.

Pharmacy check100 facilities
Registered 503B—
With a Form 483—

Where are the registered outsourcing facilities?

16 of the 100 facilities on FDA’s list are in Florida. The chart counts them by state; choose a view to see which ones FDA has inspected.

Facilities by stateFDA list, November 17, 2026
Show
Facilities—
Top state—

Which other facilities are in the same state?

What does it mean that a pharmacy is a 503B outsourcing facility?

An outsourcing facility is a compounder that has chosen to register with FDA under section 503B of the Federal Food, Drug, and Cosmetic Act. It must re-register every year between October 1 and December 31 and pay an annual fee; a facility that does not is removed from FDA’s list on January 1.1 Once registered, it joins the list of facilities FDA plans to inspect on a risk-based schedule.1

A Form FDA 483 lists what investigators observed during an inspection. FDA states that a 483 is issued when investigators see significant objectionable conditions, and that it is not a final agency determination that the law was broken.1 Registration is not FDA approval of the drugs a facility makes: compounded drugs are not FDA-approved.

Sources

  1. FDA. Facilities registered as human drug compounding outsourcing facilities under section 503B, updated November 17, 2026, with its notes on registration and inspections. fda.gov
  2. FDA. Form FDA 483, inspection of BayCare Integrated Service Center, LLC dba BayCare Central Pharmacy, 2/17/2026 to 3/12/2026. fda.gov
  3. FDA. Drug recall enforcement reports for BayCare Integrated Service Center, LLC dba BayCare Central Pharmacy, read through openFDA on November 20, 2026. open.fda.gov

Log every dose in mg with the vial it came from, so there is a record if something goes wrong.

Open Dose Insider